<DOC>
	<DOCNO>NCT01479348</DOCNO>
	<brief_summary>Background : - The drug FdCyd ( also call 5-fluoro-2'-deoxcytidine ) THU ( also call tetrahydrouridine ) use cancer treatment study . Not lot know FdCyd work body . Researchers want look modify form FdCyd use image study see drug reacts cancer . This study treatment study . It open people already FdCyd THU cancer treatment study . Objectives : - To study FdCyd affect advance cancer cell . Eligibility : - Participants National Cancer Institute study 09-C-0214 . Design : - Participants two image study , one start FdCyd THU treatment one starting treatment . - Participants modify FdCyd , know F-18 FdCyd , dose THU . The dos follow two image study scan frequent blood sample . - This procedure repeat later date , FdCyd THU treatment period . - Treatment provide part study . This imaging study protocol ... .</brief_summary>
	<brief_title>Imaging Study FdCyd THU Cancer Treatment</brief_title>
	<detailed_description>BACKGROUND : - In pre-clinical model , 5-fluoro-2 -deoxycytidine ( FdCyd ) , administer along tetrahydrouridine ( THU ; inhibitor cytidine/deoxycytidine deaminase ) , show superior anti-tumor activity compare 5-fluorouracil . - FdCyd phosphorylated 5-fluoro-2 -deoxycytidylate ( FdCMP ) deoxycytidine kinase nucleotide deaminate FdUMP deoxycytidylate ( dCMP ) deaminase . The activity dCMP deaminase report high human malignancy normal tissue , may result selective cytotoxicity . - FdCyd inhibitor DNA methyltransferase DNA methylation , result reexpression gene silence DNA hypermethylation . It evaluate phase II multihistology clinical trial Developmental Therapeutics Clinic , NCI , Clinical Center , NIH . - While FdCyd + THU show preliminary evidence activity early phase trial patient show clinical response . The establishment radiolabeled form image biodistribution vivo baseline therapy may provide insight distribution therapeutic drug . - The first step development vivo marker determine biodistribution safety radiolabeled form . OBJECTIVES : - Determine safety [ F-18 ] -5-fluoro-2'-deoxycytidine ( FdCyd ) administer intravenously administration tetrahydrouridine ( THU ) . - Estimate radiation dosimetry [ F-18 ] -FdCyd human . ELIGIBILITY : - Only patient enrol NCI Phase II Study evaluate FdCyd THU ( NCI Protocol # 09-C-0214 ( CTEP # 8351 ) NCI Protocol # 12-C-0066 ( CTEP # 9127 ) ) NIH Clinical Center eligible participate study ) . - Patients must target lesion great equal 10mm - May pregnant lactating ; must less equal 350 lb ; may know allergy FdCyd contraindication PET/CT imaging . DESIGN : - There two arm study - The first arm patient enrol therapeutic Phase II 5-FdCyd/THU study ( NCI Protocol # 09-C-0214 ( CTEP # 8351 ) NCI Developmental Therapeutics Clinic - The second arm patient enrol Phase I 5-FdCyd/THU study ( NCI Protocol # 12-C-0066 ( CTEP # 9127 ) ) NCI Developmental Therapeutics Clinic . - Patients undergo initial [ F-18 ] -FdCyd + THU PET/CT image prior therapeutic dosing study NCI Protocol # 09-C-0214 ( CTEP # 8351 ) NCI Protocol # 12-C-0066 ( CTEP # 9127 ) . Repeat image perform patient receive FdCyd + THU therapy parent therapeutic protocol . This imaging must complete 2-5 day cycle start least 2 hour dose . Upon completion repeat imaging , patient take image study 24 hour last imaging session .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Tetrahydrouridine</mesh_term>
	<criteria>INCLUSION CRITERIA : Enrolled NIH Phase II Clinical protocol evaluate FdCyd THU ( 09C0214 ) target lesion measure great equal 10mm spiral CT scan . Written , voluntary , informed consent patient must obtain compliance institutional , state federal guideline For female : Negative serum pregnancy test OR postmenopausal least 2 year OR patient hysterectomy EXCLUSION CRITERIA : Participants severe claustrophobia unresponsive oral anxiolytic Subjects weigh &gt; 400 lb ( weight limit scanner table ) , unable fit within image gantry Known allergy FdCyd The subject unable lie still 75 minute 5 Pregnant lactate woman . Pregnant woman exclude study effect 18FFdCyd pregnancy know . Because unknown potential risk adverse event nurse infant secondary administration 18FFdCyd mother , breastfeed discontinue mother receive 18FFdCyd Participants coexist medical psychiatric condition likely interfere study procedure and/or result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 17, 2017</verification_date>
	<keyword>Imaging</keyword>
	<keyword>Radiopharmaceutical</keyword>
	<keyword>Safety</keyword>
	<keyword>Dosimetry</keyword>
	<keyword>Drug Distribution</keyword>
	<keyword>Cancer</keyword>
</DOC>